Infosheets

Results of previous calls
Programmes EDF

Published on | 1 year ago

Last updated on | 3 weeks ago

Author Do you have an additional question? Or spotted a mistake? Don't hesitate to contact me!
Image of Mark Antonissen
Mark Antonissen

mark.antonissen@vlaio.be

Result of the EDF 2023 Calls for Proposals

Following the third calls for proposals under the European Defence Fund (EDF), 54 collaborative defence research and development projects with a total EU support of almost €1,031million are selected for funding.

Result of the EDF 2022 Calls for Proposals

Following the second calls for proposals under the European Defence Fund (EDF), 41 collaborative defence research and development projects with a total EU support of almost €832 Million are selected for funding.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.